NAMD Comments on Proposed Rule that Would Require Medicaid Coverage of Anti-Obesity Medications
In December 2024, CMS issued a proposed rule that would require Medicaid to cover anti-obesity medications.
Letter ·
NAMD Comments on Senate Finance Committee’s Generic Drug Legislation
The legislation would exclude most generic drugs from the Medicaid Drug Rebate Program’s inflationary rebates.
On June 7, NAMD submitted comments on the Senate Finance Committee’s draft legislation on generic drug shortages. In our comments, we highlight concerns that the legislation, as written, would weaken the Medicaid Drug Rebate Program and fail to address the root causes of generic drug shortages.
Related resources
Breaking the Bottleneck: Modernizing Medicaid Drug Access in the Million Dollar Therapy Era
NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS's proposed rule on the Medicaid Drug Rebate Program (MDRP).
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.